The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Open accessAbstract
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There are 80 FDA-approved therapeutic agents that target about two dozen different protein kinases and seven of these drugs were approved in 2023. Of the approved drugs, thirteen target protein-serine/threonine protein kinases, four are directed against dual specificity protein kinases (MEK1/2), twenty block nonreceptor protein-tyrosine kinases, and 43 inhibit receptor protein-tyrosine kinases. The data indicate that 69 of these drugs are prescribed for the treatment of neoplasms. Six drugs (abrocitinib, baricitinib, deucravacitinib, ritlecitinib, tofacitinib, upadacitinib) are used for the treatment of inflammatory diseases (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, and ulcerative colitis). Of the 80 approved drugs, nearly two dozen are used in the treatment of multiple diseases. The following seven drugs received FDA approval in 2023: capivasertib (HER2-positive breast cancer), fruquintinib (metastatic colorectal cancer), momelotinib (myelofibrosis), pirtobrutinib (mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma), quizartinib (Flt3-mutant acute myelogenous leukemia), repotrectinib (ROS1-positive lung cancer), and ritlecitinib (alopecia areata). All of the FDA-approved drugs are orally effective with the exception of netarsudil, temsirolimus, and trilaciclib. This review summarizes the physicochemical properties of all 80 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, polar surface area, potency, solubility, lipophilic efficiency, and ligand efficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 2×
“Furthermore, Veber et al. reported that medicinals with a polar surface area less than or equal to 140 Å 2 are orally effective [104].”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403 · cited 1×
“Leeson and Springthorpe re-ported that drug lipophilicity, as assessed by its – ALogP value, is a key property that should be monitored during drug development [100].”
The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1
Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Self-citationThe ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Self-citationDeficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I., Sparkes, R. S., Kubagawa, H., Mohandas, T., Quan, S., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90667-f · Cited by 1,327
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Self-citationTrends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Self-citationMolecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Self-citationA historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Self-citationThrough the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901443h · Cited by 518
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504 · cited 2×
“This compound is a potent inhibitor of ROS1, ALK, and NTRKA/B/C [83].”
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 487
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
A helix scaffold for the assembly of active protein kinases
Kornev, A. P., Taylor, S. S., & Ten Eyck, L. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807988105 · Cited by 442
Li, J., Qin, S., Xu, R.-H., Shen, L., Xu, J., Bai, Y., Yang, L., Deng, Y., Chen, Z.-D., Zhong, H., et al. (2018) · JAMA · doi:10.1001/jama.2018.7855 · Cited by 425
The first general index of molecular complexity
Bertz, S. H. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00402a071 · Cited by 414
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Self-citationThe Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
RAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 376
Self-citationJanus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 373
Self-citationDefining a new nomenclature for the structures of active and inactive kinases
Modi, V., & Dunbrack, R. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814279116 · Cited by 367
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105463 · Cited by 335
Self-citationSasaki, K., Strom, S. S., O'Brien, S., Jabbour, E., Ravandi, F., Konopleva, M., Borthakur, G., Pemmaraju, N., Daver, N., Jain, P., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00048-4 · Cited by 318
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Self-citationAnaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Self-citationKLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 298
Dynamics-Driven Allostery in Protein Kinases
Kornev, A. P., & Taylor, S. S. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.002 · Cited by 284
MEK1/2 dual-specificity protein kinases: Structure and regulation
Roskoski, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.145 · Cited by 276
Self-citationMadhusudan, Trafny, E. A., Xuong, N., Adams, J. A., Eyck, L. F. T., Taylor, S. S., & Sowadski, J. M. (1994) · Protein Science · doi:10.1002/pro.5560030203 · Cited by 274
Defining the conserved internal architecture of a protein kinase
Kornev, A. P., & Taylor, S. S. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.10.017 · Cited by 266
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Roskoski, R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.010 · Cited by 260
Self-citationCyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Self-citationAsshoff, M., Petzer, V., Warr, M. R., Haschka, D., Tymoszuk, P., Demetz, E., Seifert, M., Posch, W., Nairz, M., Maciejewski, P., et al. (2017) · Blood · doi:10.1182/blood-2016-09-740092 · Cited by 233
Addie, M., Ballard, P., Buttar, D., Crafter, C., Currie, G., Davies, B. R., Debreczeni, J., Dry, H., Dudley, P., Greenwood, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301762v · Cited by 230
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 218
Self-citationDeciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Meharena, H. S., Chang, P., Keshwani, M. M., Oruganty, K., Nene, A. K., Kannan, N., Taylor, S. S., & Kornev, A. P. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001680 · Cited by 208
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective: Miniperspective
Myers, S. H., Brunton, V. G., & Unciti-Broceta, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01273 · Cited by 203
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 201
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
Roskoski Jr., R. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106037 · Cited by 198
PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
Carles, F., Bourg, S., Meyer, C., & Bonnet, P. (2018) · Molecules · doi:10.3390/molecules23040908 · Cited by 197
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Self-citationApproaches to discover non-ATP site kinase inhibitors
Gavrin, L. K., & Saiah, E. (2013) · MedChemComm · doi:10.1039/c2md20180a · Cited by 184
Cortes, J., Pavlovsky, C., & Saußele, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01204-6 · Cited by 184
New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Lamba, V., & Ghosh, I. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672813 · Cited by 182
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
Target-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies
Leeson, P. D., Bento, A. P., Gaulton, A., Hersey, A., Manners, E. J., Radoux, C. J., & Leach, A. R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00416 · Cited by 176
KLIFS: a structural kinase-ligand interaction database
Kooistra, A. J., Kanev, G. K., van Linden, O. P. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1082 · Cited by 174
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.021 · Cited by 170
Self-citationJabbour, E., Kantarjian, H., & Cortes, J. (2015) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2015.03.006 · Cited by 164
New Promise and Opportunities for Allosteric Kinase Inhibitors
Lu, X., Smaill, J. B., & Ding, K. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201914525 · Cited by 164
KLIFS: an overhaul after the first 5 years of supporting kinase research
Kanev, G. K., de Graaf, C., Westerman, B. A., de Esch, I. J. P., & Kooistra, A. J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa895 · Cited by 163
Sun, Q., Zhou, J., Zhang, Z., Guo, M., Liang, J., Zhou, F., Long, J., Zhang, W., Yin, F., Cai, H., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.964087 · Cited by 159
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src
Liu, Y., Shah, K., Yang, F., Witucki, L. A., & Shokat, K. M. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00099-6 · Cited by 156
The Landscape of Atypical and Eukaryotic Protein Kinases
Kanev, G. K., de Graaf, C., de Esch, I. J. P., Leurs, R., Würdinger, T., Westerman, B. A., & Kooistra, A. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.002 · Cited by 153
Roskoski, R. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104567 · Cited by 153
Self-citationDrugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 140
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.022 · Cited by 138
Self-citationQuality guidelines for oral drug candidates: dose, solubility and lipophilicity
Bayliss, M. K., Butler, J., Feldman, P. L., Green, D. V. S., Leeson, P. D., Palovich, M. R., & Taylor, A. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.007 · Cited by 133
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.007 · Cited by 133
Self-citationKincore: a web resource for structural classification of protein kinases and their inhibitors
Modi, V., & Dunbrack, R. L. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab920 · Cited by 133
Molecular complexity: a simplified formula adapted to individual atoms
Hendrickson, J. B., Huang, P., & Toczko, A. G. (1987) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00054a004 · Cited by 132
Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery
Ritchie, T. J., & Macdonald, S. J. F. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500515d · Cited by 120
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 119
Self-citationCrystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
Zorn, J. A., Wang, Q., Fujimura, E., Barros, T. F., & Kuriyan, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121177 · Cited by 118
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Roskoski, R. J., & Sadeghi‐Nejad, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.021 · Cited by 118
Self-citationJanus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Roskoski, R. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106362 · Cited by 113
Self-citationGuidelines for preparing color figures for everyone including the colorblind
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.005 · Cited by 112
Self-citationThe new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
Bechman, K., Yates, M., & Galloway, J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104392 · Cited by 112
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
Xie, Z., Yang, X., Duan, Y., Han, J., & Liao, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01511 · Cited by 111
Nițulescu, G. M., Stancov, G., Șeremet, O. C., Nițulescu, G., Mihai, D. P., Duta-Bratu, C.-G., Bărbuceanu, Ș., & Olaru, O. T. (2023) · Molecules · doi:10.3390/molecules28145359 · Cited by 111
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification
Wells, C. I., Al‐Ali, H., Andrews, D. M., Asquith, C. R. M., Axtman, A. D., Chung, M., Đikić, I., Ebner, D. V., Elkins, J. M., Ettmayer, P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020566 · Cited by 109
Cui, J. J., McTigue, M. A., Nambu, M. D., Tran‐Dubé, M., Pairish, M., Shen, H., Jia, L., Cheng, H., Hoffman, J. E., Le, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300967g · Cited by 108
Redefining the Protein Kinase Conformational Space with Machine Learning
Ung, P. M. U., Rahman, R., & Schlessinger, A. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.002 · Cited by 104
From structure to the dynamic regulation of a molecular switch: A journey over 3 decades
Taylor, S. S., Wu, J., Bruystens, J. G. H., Rio, J. C. D., Lu, T., Kornev, A. P., & Eyck, L. F. T. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100746 · Cited by 98
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.011 · Cited by 94
Self-citationOrally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105422 · Cited by 93
Self-citationParticipation of ADP Dissociation in the Rate-Determining Step in cAMP-Dependent Protein Kinase
Zhou, J., & Adams, J. A. (1997) · Biochemistry · doi:10.1021/bi971438n · Cited by 91
Inhibition of T-cell activity in alopecia areata: recent developments and new directions
Passeron, T., King, B., Sénéschal, J., Steinhoff, M. S., Jabbari, A., Ohyama, M., Tobin, D. J., Randhawa, S., Winkler, A. R., Telliez, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243556 · Cited by 91
Murray, B. W., Rogers, E., Zhai, D., Deng, W., Chen, X., Sprengeler, P. A., Zhang, X., Graber, A., Reich, S. H., Stopatschinskaja, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0632 · Cited by 90
Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Bajusz, D., Ferenczy, G. G., & Keserű, G. M. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170224121313 · Cited by 88
Haddad, F., Sasaki, K., Issa, G. C., Garcia‐Manero, G., Ravandi, F., Kadia, T. M., Cortes, J. E., Konopleva, M. Y., Pemmaraju, N., Alvarado, Y., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26550 · Cited by 87
Crowdsourced mapping of unexplored target space of kinase inhibitors
Cichońska, A., Ravikumar, B., Allaway, R. J., Wan, F., Park, S., Isayev, O., Li, S., Mason, M., Lamb, A. E., Tanoli, Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23165-1 · Cited by 86
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.020 · Cited by 80
Self-citationKinaseMD: kinase mutations and drug response database
Hu, R., Xu, H., Jia, P., & Zhao, Z. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa945 · Cited by 78
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Roskoski, R. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106156 · Cited by 70
Self-citationTefferi, A., Pardanani, A. D., & Gangat, N. (2023) · Haematologica · doi:10.3324/haematol.2022.282612 · Cited by 67
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105579 · Cited by 63
Self-citationThe cure of leukemia through the optimist's prism
Kantarjian, H. M., Jain, N., Garcia‐Manero, G., Welch, M. A., Ravandi, F., Wierda, W. G., & Jabbour, E. J. (2021) · Cancer · doi:10.1002/cncr.33933 · Cited by 54
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105806 · Cited by 40
Self-citationRoskoski, R. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.813015 · Cited by 39
Self-citationRoskoski, R. J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104725 · Cited by 38
Self-citationRoskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105660 · Cited by 37
Self-citationA decade with agammaglobulinemia
Bruton, O. C. (1962) · The Journal of Pediatrics · doi:10.1016/s0022-3476(62)80092-4 · Cited by 36
Posttranslational modifications as therapeutic targets for intestinal disorders
Choo, J., Heo, G., Pothoulakis, C., & Im, E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105412 · Cited by 22
Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?
Dainichi, T., Iwata, M., & Kaku, Y. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.17064 · Cited by 21
Surprising Non-Additivity of Methyl Groups in Drug–Kinase Interaction
Wienen-Schmidt, B., Schmidt, D., Gerber, H., Heine, A., Gohlke, H., & Klebe, G. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00476 · Cited by 20
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods
Ekins, S., Litterman, N. K., Lipinski, C. A., & Bunin, B. A. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1779-y · Cited by 19
Roskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107036 · Cited by 19
Self-citationMesa, R. A., Hudgens, S. A., Floden, L. L., Harrison, C. N., Palmer, J. M., Gupta, V. K., McLornan, D. P., McMullin, M. F., Kiladjian, J., Foltz, L. M., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5799 · Cited by 16
Gao, L., Tang, L., Hu, Z., Peng, J., Li, X., & Liu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1269203 · Cited by 11
Akwata, D., Kempen, A. L., Dayal, N., Brauer, N. R., & Sintim, H. O. (2023) · ChemMedChem · doi:10.1002/cmdc.202300442 · Cited by 10
Gaining MOMENTUM against anaemic myelofibrosis
Ikeda, K., & Ueda, K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00171-x · Cited by 4
Cited by
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
Docking-Informed Machine Learning for Kinome-wide Affinity Prediction
Schifferstein, J., Bernatavicius, A., & Janssen, A. P. A. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01260 · Cited by 8
Burtscher, M. L., Garrido-Rodriguez, M., Rivera Mejias, P. A., Papagiannidis, D., Becher, I., Selegato, D. M., Potel, C., Jung, F., Zimmermann, M., Saez-Rodriguez, J., et al. (2026) · bioRxiv · doi:10.64898/2026.02.09.704793
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2024-02
- Volume
- 200
- Pages
- 107059
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W4390747020
- Cited by
- 383
- References
- 122
- FWCI
- 44.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.